Navigation Links
Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
Date:4/26/2012

d treatment setting and suggests the effect of adding Vimpat® as an adjunctive therapy after initial monotherapy. These results need to be confirmed by the final analysis when the study concludes," said Matthias Noack-Rink, lead study author and Medical Affairs Director, Epilepsy, UCB Germany.

Vimpat® is indicated as an adjunctive therapy for the treatment of partial-onset seizures in adults with epilepsy.  The most common adverse reactions reported in pivotal trials and occurring in 10 percent or more of lacosamide-treated patients, and greater than placebo, were dizziness, headache, nausea and diplopia.  Additional important safety information for Vimpat® is available at the end of the press release.

About Epilepsy
Epilepsy is a chronic neurological disorder affecting approximately 50 million people worldwide and 3 million people in the U.S. Anyone can develop epilepsy; it occurs across all ages, races and genders.  Uncontrolled seizures and medication side effects pose challenges to independent living, learning and employment, so the goal of epilepsy treatment is seizure freedom with minimal side effects.  More than 1 million patients in the U.S. continue to have seizures despite initial therapy, and more than 800,000 patients in the U.S. continue to have seizures despite treatment with two or more therapies. [1],[2]

About Vimpat
Vimpat® tablets and injection were launched in the US in May 2009 as an add-on therapy for the treatment of partial-onset seizures in people with epilepsy who are aged 17 years and older.  Vimpat® injection is a short-term replacement when oral administration is not feasible in these patients.  Vimpat® oral solution was launched in June 2010.  The availability of the oral tablets, oral solution, and IV injection allows for consistent treatment in a hospital setting.  The most common adverse reactions occurring in gr
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
11. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Calif. and BRUSSELS ... AMGN ) and UCB (Euronext Brussels: UCB) today ... evaluating effect of RomosozUmab Compared with Teriparatide in ... fracture pReviously treated with bisphosphonatE therapy). The study ... significant difference in favor of romosozumab in the ...
(Date:9/1/2015)... Sept. 1, 2015 Emerus Holdings, a ... emergent, inpatient and diagnostic care in partnership with ... a definitive agreement to receive a strategic investment ... a leading health care investment firm. ... patient-centric acute episodic and ambulatory clinical services to ...
(Date:9/1/2015)... IRVINE, Calif. , Sept. 1, 2015  Edwards ... in the science of heart valves and hemodynamic monitoring, ... Fargo Healthcare Conference at the Hyatt Regency Boston in ... 9, 2015. Michael A. Mussallem , ... keynote lunch speaker followed by a company discussion with ...
Breaking Medicine Technology:Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3
... /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (NASDAQ: ... emerging leader in the development, assembly, marketing and sale ... that the Company,s growing business earned a BBB+ Credit Rating ... "Zhongguancun Association") and was approved as a member of ...
... SHANGHAI, Feb. 28, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: ... China-based pharmaceutical and biotechnology research and development outsourcing company, ... results for the fourth quarter and full year ended ... host a conference call to discuss the results at ...
Cached Medicine Technology:Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 2Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 3ShangPharma to Report Fourth Quarter and Full Year 2011 Financial Results on March 13, 2012 2
(Date:9/1/2015)... ... September 01, 2015 , ... As ... Cross and Blue Shield of Minnesota (Blue Cross) has announced Doctor On Demand ... in San Francisco, Doctor On Demand provides immediate access to Board Certified physicians ...
(Date:9/1/2015)... Houston, TX (PRWEB) , ... September 01, 2015 ... ... announce that it is now offering the MonaLisa Touch® , an innovative ... , The MonaLisa Touch® is a new hormone-free treatment for atrophic vaginitis, a ...
(Date:9/1/2015)... ... September 01, 2015 , ... PetPace, ... of pet vital signs and activity, today announced its integration with leading veterinary ... popular and widely-adopted veterinary hospital Practice Management Software packages in the US. Practice ...
(Date:9/1/2015)... ... ... Royal River Natural Foods, a locally-owned independent natural health store in Freeport, ... and found that, among those who had a stroke, people who used multivitamins survived ... the September 2015 issue of “Natural Insights for Well Being,” which Royal River Natural ...
(Date:9/1/2015)... ... 01, 2015 , ... Two of Washington D.C.’s most respected chefs are using ... , Recently named “the next big thing” in the culinary world by Elle ... whole story behind food and reclaiming culinary traditions on the brink of extinction. According ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 4
... ... Shelton, O’Leary & Peterson, LLC, has been appointed to the Plaintiffs, Steering Committee in the ... ... partner with Onder, Shelton, O’Leary & Peterson, LLC, was appointed by U.S. District Judge David ...
... , , BOSTON, Nov. 14 Joslin ... care organization, has completed a major overhaul of its ... for patients, researchers, healthcare professionals and the public. , ... Joslin.org website," said Michael Sullivan, Senior Vice President for ...
... of senior athletes finds better density with some sports, ... sports might help boost bone mineral density in mature ... male and female athletes, aged 50 to 93, who ... Pittsburgh, including 560 who competed in high-impact sports such ...
... ... shipping. , ... 2009 -- Medical scrubs begin to look worn more quickly than other clothing items and ... every year. If you are looking for a great place to purchase scrubs, blue ...
... , WASHINGTON, Nov. 14 ... Bureau: , (Logo: http://www.newscom.com/cgi-bin/prnh/20090226/CENSUSLOGO ) , ... Profile America -- Saturday, November 14th. Each year, ... the public aware of the serious nature of the disease, and ...
... ... Claims and Practices of Mind Control Cult. Inspired by numerous responses to ... second book, AMORC Unmasked! This book goes into greater depth, exposing the ... Crucis, commonly called AMORC, but also defending the possibility for a true ...
Cached Medicine News:Health News:Federal Court Appoints Onder Law Firm Partner as Co-Lead Counsel to the Plaintiffs' Steering Committee of the Multi-District Litigation for Yasmin and Yaz Litigation 2Health News:Federal Court Appoints Onder Law Firm Partner as Co-Lead Counsel to the Plaintiffs' Steering Committee of the Multi-District Litigation for Yasmin and Yaz Litigation 3Health News:High-Impact Activity May Be Good for Old Bones 2Health News:blue sky scrubs adds Caribbean Blue Scrubs 2Health News:Pierre S. Freeman Adds Book AMORC Unmasked! To his Arsenal of Whistleblower Weapons Aimed at Rosicrucian Order 2Health News:Pierre S. Freeman Adds Book AMORC Unmasked! To his Arsenal of Whistleblower Weapons Aimed at Rosicrucian Order 3
... The SeedVac™ is a vacuum driven device designed to ... tube tip. Seeds are drawn into the clear tube ... the hand piece to create the vacuum. The prescribed ... the clear tube tip before being placed into the ...
MT-BT-5001-25 prostate seeding needle (set of 25 unloaded needles).,MT-BT-5001-P prostate seeding needle, pre-plugged and pre-sterilized, unloaded or for use with MEDTECs ASAP™ pre-load seeding...
... a myoma was performed with a cutting ... vaporization of myomas with the VaporTrode Vaporization ... tissue chips that obscure visibility. No tissue ... This unique design provides areas of high ...
... The 19 Fr. OES 4000 Nephroscope, with ... quality with outstanding durability. The lumbotome, for ... the telescopic bougies, allow safer access. The ... comprehensive range of grasping forceps and lithotripsy ...
Medicine Products: